marked.bio

ATR inhibitor · small molecule

ceralasertib

4 active trials across 2 of our biomarkers, targeting ATR. Not approved for any biomarker on marked.bio yet.

Also known as AZD6738.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
BRCA1/2 mutation 3 4 Phase 2
IDH1/2 mutation 1 1 Phase 2

Sponsors

Industry sponsors leading active biomarker-selected trials of ceralasertib.

  1. AstraZeneca 1

Trials

4 of 5 trials shown

  1. Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer

    Recruiting Phase 2 M.D. Anderson Cancer Center Started 2020Primary completion 2027-12 NCT04090567

    Cediranibceralasertibolaparib FDA EU

    Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer

    BRCA1/2 mutationAdvanced Breast Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8

  2. Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors

    Active, not recruiting Phase 2 National Cancer Institute (NCI) Started 2020Primary completion 2025-03 NCT03878095

    ceralasertibolaparib

    Patients must have biopsy-confirmed evidence of an IDH1 or IDH2 mutation, confirmed in a Clinical Laboratory Improvement Act (CLIA)-certified laboratory, associat…

    IDH1/2 mutationMalignant Solid Neoplasm, Refractory Cholangiocarcinoma, Refractory Malignant Solid Neoplasm

  3. Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

    Active, not recruiting Phase 2 M.D. Anderson Cancer Center Started 2018Primary completion 2026-12 NCT03579316

    adavosertibolaparib FDA EUceralasertib

    Are germline or somatic BRCA mutant or HRD positive by a licensed test prior to enrollment.

    BRCA1/2 mutationRecurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma

  4. Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents

    Active, not recruiting Phase 1 AstraZeneca Started 2014Primary completion 2025-03 NCT02264678

    ceralasertibolaparib FDA EUdurvalumabsaruparibcarboplatin

    Module 5 Part B: known or suspected BRCA mutation, PALB2 mutation, RAD51C/D mutation or HRD positive status

    BRCA1/2 mutationAdv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer